Clinical Trials
118 trialsNCT07428486 2026-05-07
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT07093086 2026-05-06
Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1 Withdrawn
NCT07453446 2026-05-06
Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1 Withdrawn
NCT07498465 2026-05-05
A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia
Children's Oncology Group
Phase 1 Withdrawn
NCT07049432 2026-04-01
CARMEN-803
University of Utah
Phase 1 Withdrawn
NCT05170828 2026-02-24
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
Phase 1 Withdrawn
NCT05263739 2025-09-12
A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies
Shanghai Escugen Biotechnology Co., Ltd
Phase 1 Withdrawn
NCT04500548 2025-09-10
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT05521087 2025-06-22
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
Janssen Research & Development, LLC
Phase 1 Withdrawn
NCT04556266 2025-05-13
A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies
Memorial Sloan Kettering Cancer Center
Phase 1 Withdrawn
NCT06290622 2025-05-06
PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL
University of Alabama at Birmingham
Phase 1 Withdrawn
NCT02548468 2025-05-02
Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma
Thomas Jefferson University
Phase 1 Withdrawn
NCT06238531 2025-03-13
A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT04781855 2025-02-28
Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT04052061 2025-02-21
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
ImmunityBio, Inc.
Phase 1 Withdrawn
NCT02743546 2025-02-03
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
Janssen Research & Development, LLC
Phase 1 Withdrawn
NCT03939585 2024-12-05
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
Case Comprehensive Cancer Center
Phase 1 Withdrawn
NCT05487495 2024-11-14
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma
Beijing Boren Hospital
Phase 1 Withdrawn
NCT06003179 2024-11-12
LOKI
University Health Network, Toronto
Phase 1 Withdrawn
NCT05134740 2024-10-22
pediTACTAL
Baylor College of Medicine
Phase 1 Withdrawn
NCT04995536 2024-04-25
CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL
City of Hope Medical Center
Phase 1 Withdrawn
NCT05796271 2024-02-29
Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy
The University of Texas Health Science Center at San Antonio
Phase 1 Withdrawn
NCT05321940 2023-12-04
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
University of Miami
Phase 1 Withdrawn
NCT05259813 2023-11-24
Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 1 Withdrawn
NCT05867030 2023-10-17
Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Withdrawn
NCT05961696 2023-10-10
A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT03884972 2023-09-25
Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT04952584 2023-09-07
Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas
Baylor College of Medicine
Phase 1 Withdrawn
NCT05519527 2023-08-31
STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT05934097 2023-07-06
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
Fate Therapeutics
Phase 1 Withdrawn
NCT05037669 2023-06-22
Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma
University of Pennsylvania
Phase 1 Withdrawn
NCT01316146 2023-03-22
Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)
UNC Lineberger Comprehensive Cancer Center
Phase 1 Withdrawn
NCT05513612 2023-03-01
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
Shanghai Pudong Hospital
Phase 1 Withdrawn
NCT05176691 2023-02-21
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
Hutchmed
Phase 1 Withdrawn
NCT04877080 2023-02-10
CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1 Withdrawn
NCT03338881 2023-02-08
A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies
Calithera Biosciences, Inc
Phase 1 Withdrawn
NCT03359733 2023-02-08
A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor
Calithera Biosciences, Inc
Phase 1 Withdrawn
NCT03772288 2023-02-08
A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)
Calithera Biosciences, Inc
Phase 1 Withdrawn
NCT05251376 2023-01-19
Study of LYN-014 in Individuals With Opioid Use Disorder Who Are Stable on Methadone Therapy
Lyndra Inc.
Phase 1 Withdrawn
NCT05228249 2023-01-13
Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma
Fred Hutchinson Cancer Center
Phase 1 Withdrawn
NCT05168748 2022-12-21
CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia
Novartis
Phase 1 Withdrawn
NCT04639843 2022-11-04
Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT04635683 2022-09-30
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Withdrawn
NCT03768310 2022-07-21
CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)
Baylor College of Medicine
Phase 1 Withdrawn
NCT04836832 2022-06-07
Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Withdrawn
NCT04974996 2022-03-29
LOTIS-8
ADC Therapeutics S.A.
Phase 1 Withdrawn
NCT03639324 2021-11-09
RIVe-CLL/SLL
Virginia Commonwealth University
Phase 1 Withdrawn
NCT04464889 2021-10-08
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Medigene AG
Phase 1 Withdrawn
NCT03605589 2021-04-01
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
Children's Hospital Medical Center, Cincinnati
Phase 1 Withdrawn
NCT03920631 2021-03-23
MicroBLITZ
Duke University
Phase 1 Withdrawn